SRNE News Alert Sorrento Therapeutics (SRNE) 8.25 12/17/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Sorrento Therapeutics (SRNE) 8.25 $SRNE

Perception, Opportunity in Volatility: Analyst Notes on Oracle, Riverbed, ExxonMobil, Sorrento Therapeutics and AES
PR Newswire - Tue Dec 16, 8:30AM CST
Moments ago, Realtime Equities released new analyst updates concerning several important developing situations. Realtime Equities is the leader in realtime news, commentary and analysis - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
SRNE: 8.25 (+0.95)

Sorrento up on news of collaboration with Abraxane inventor
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 12:40PM CST

SRNE: 8.25 (+0.95)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:52AM CST

FRO: 2.29 (-0.58), JRJC: 5.70 (-0.88), TLM: 7.58 (+2.46), SPHS: 0.45 (-0.07), DAKP: 1.44 (-0.05), PHMD: 1.14 (+0.09), HGSH: 4.67 (-0.90), ARDX: 23.32 (+0.26), SRNE: 8.25 (+0.95), NYNY: 7.97 (+0.53), MFI: 10.20 (+0.01), ANFI: 9.66 (-0.44), LNCO: 10.87 (+1.71), QTWW: 2.35 (+0.19), IKGH: 1.34 (+0.09), CRUS: 22.89 (-0.07), MPO: 1.42 (+0.26), LINE: 12.54 (+2.71), CGG: 6.24 (+0.13), UPIP: 0.91 (+0.06)

Sorrento Announces Strategic Investment By And Collaboration With Nantworks Founder Dr. Patrick Soon-Shiong For The Advancement Of Cancer Immunotherapies
PR Newswire - Mon Dec 15, 8:25AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced today that it has entered into a binding agreement with NantWorks founder, physician scientist, and biotechnology entrepreneur Dr. Patrick Soon-Shiong.
SRNE: 8.25 (+0.95)

Sorrento Therapeutics Announces Poster Presentations on its Anti-c-Met/PD-L1 Bispecific Antibodies and Anti-c-Met-Antibody Drug Conjugate at the 37th Annual San Antonio Breast Cancer Symposium
PR Newswire - Mon Dec 08, 8:15AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, announced today that it will present preclinical data on their bispecific antibodies (BsAbs) and antibody drug conjugates (ADCs) against c-Met in breast cancer at the 37th Annual San Antonio Breast Cancer Symposium in San Antonio, Texas. Highlights of the findings include preclinical data on generation and evaluation of: i) anti-c-Met/anti-PD-L1 and anti-c-Met/anti-ErbB3 BsAbs, and ii) an anti-c-Met ADC as new immunotherapeutic strategies in breast cancer.
SRNE: 8.25 (+0.95)

Sorrento To Present At The 2014 Oppenheimer Healthcare Conference
PR Newswire - Wed Dec 03, 8:30AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, today announced that Dr. Henry Ji, President and Chief Executive Officer, will present at the 2014 Oppenheimer Healthcare Conference on Thursday, December 11, 2014 at 2:45 pm ET in the Act I Room at the Crowne Plaza Hotel in New York City.
SRNE: 8.25 (+0.95)

Initial Pharmacokinetic Data From TRIBECA Study Support Potential For Bioequivalence Between Cynviloq And Albumin-Bound Paclitaxel
PR Newswire Europe - Wed Nov 26, 1:31PM CST
Sorrento Therapeutics, Inc. , an oncology company developing new treatments for cancer and associated pain, announced today positive results from recently analyzed pharmacokinetic (PK) data from the first eight (8) patients enrolled in its ongoing TRIBECA(TM) (TRIal establishing BE between Cynviloq(TM) and Albumin-bound paclitaxel) registrational trial. The data from these patients supports earlier completion of the study with the aim of seeking to establish bioequivalence (BE) to albumin-bound paclitaxel to obtain Food and Drug Administration (FDA) marketing approval for Cynviloq (paclitaxel polymeric micelle for injection).
SRNE: 8.25 (+0.95)

Rolling With Biotech's Regulatory Punches: Chen Lin
Life Sciences Report - Seeking Alpha - Tue Nov 25, 3:36PM CST
Being temporarily burned by the U.S. Food and Drug Administration can be a mixed blessing for a biotech with a good product in the pipeline. In an interview with The Life Sciences Report , Chen Lin, publisher of the investor newsletter What is...
ACRX: 5.83 (-0.30), BMRN: 86.06 (-1.17), RNA: 18.55 (+0.24), SRPT: 12.60 (-0.40), MRK: 56.80 (-0.15), NLNK: 33.10 (-0.36), GSK: 41.92 (+0.62), SRNE: 8.25 (+0.95), NEPT: 1.91 (-0.01), CELG: 110.09 (-1.79)

Global Immune Checkpoint Inhibitors Market, 2014-2024: Yervoy, Opdivo and Keytruda to Achieve Blockbuster Status in the Near Future
M2 - Thu Nov 13, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/fkbg4v/immune_checkpoint) has announced the addition of the "Immune Checkpoint Inhibitors Market, 2014 - 2024" report to their offering. The Immune Checkpoint Inhibitors Market, 2014-2024 report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of Immune Checkpoint Inhibitors. The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs which can be potentially exploited for the broad range of cancer. CTLA-4 inhibitors were the pioneers in this segment. Yervoy, the flagship molecule from BMS, was the only immunotherapeutic Immune Checkpoint Inhibitor commercially available until other classes recently stepped in. The approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost to the market. Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in this domain, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and several others under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform. With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period. Specifically, we expect Yervoy, Opdivo and Keytruda to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants. Key Highlights - The market is characterized by the presence of three marketed drugs and 25 drugs in clinical development for oncological indications. This pipeline includes two CTLA-4, eight PD-1 / PD-L1 and 18 novel Immune Checkpoint Inhibitors. The dynamic pipeline also includes several molecules in preclinical / discovery stage; in our research, we identified about 30 such molecules. - BMS, with seven Immune Checkpoint Inhibitors (marketed / clinical development), is the leading player. Other pharmaceutical giants include AstraZeneca, Merck and Roche. Many university spin-offs have emerged in the past two years; their early stage research has been backed by venture funding as well. - Amongst the novel Immune Checkpoint Inhibitors, IDO inhibitors have been the most sought after drug class under development. Though Elotuzumab is the only drug in late stage development, novel checkpoints have paved the way for smaller biotechnology firms to enter the immuno-oncology market. - Collaborations have helped the market reach its current growth trajectory. Specifically, clinical trial collaborations to evaluate Immune Checkpoint Inhibitors as combination therapies are very common; 2014 has already seen 12 such collaborations for a number of molecules. - We expect Immune Checkpoint Inhibitors to be a multi-billion dollar market over the coming decade; during the period 2014 - 2024, our forecast suggests that the market will witness an annualized growth rate of 24.1%. Key Topics Covered: 1. Preface 2. Executive Summary 3. Cancer Therapeutics and Immuno-Oncology 4. Current Market Landscape 5. CTLA-4 Inhibitors: Key Molecules and Future Outlook 6. PD-1 and PD-L1 Inhibitors: Key Molecules and Future Outlook 7. Novel Immune Checkpoint Inhibitors: Key Molecules and Future Outlook 8. Competition in Key Indication Areas 9. Deals and Partnerships 10. Company Profiles 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List of Companies and Organizations Companies Mentioned - Bristol Myer Squibb - AstraZeneca - Merck & Co. - Roche / Genentech - Incyte Corporation - NewLink Genetics - arGEN-X - Seattle Genetics - Pfizer - MacroGenics - Celldex Therapeutics - CureTech - Immutep - Innate Pharma - Sorrento Therapeutics - GlaxoSmithKline - GITR, Inc. For more information visit http://www.researchandmarkets.com/research/fk...checkpoint
MRK: 56.80 (-0.15), INCY: 71.62 (-0.52), CLDX: 16.83 (-0.05), NLNK: 33.10 (-0.36), GSK: 41.92 (+0.62), BMY: 57.69 (-0.86), SRNE: 8.25 (+0.95)

Sorrento To Present At The 2014 Stifel Healthcare Conference
PR Newswire - Wed Nov 12, 10:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), today announced that Dr. Henry Ji, President and Chief Executive Officer, will present on Tuesday, November 18, 2014 at 3:00 pm ET in the Winslow Room at the New York Palace Hotel in New York City.
SRNE: 8.25 (+0.95)

Cancer Pain Therapeutics Pipeline Report 2014 - 30 Companies & 43 Drug Profiles
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s5fww/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Daiichi Sankyo Company, Limited - Egalet Corporation - Aphios Corporation - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Orion Oyj - Pfizer Inc. - Zeria Pharmaceutical Co Ltd - GW Pharmaceuticals plc - IntelGenx Corp. - Benitec Biopharma Limited - Kolon Life Science, Inc. - Teikoku Seiyaku Co., Ltd. - Aoxing Pharmaceutical Company, Inc - BCN Peptides, S.A. - Grunenthal GmbH - AngioChem Inc. - WEX Pharmaceuticals Inc. - Virobay Inc. - Dimerix Bioscience Pty Ltd - Winston Pharmaceuticals, Inc. - Encore Therapeutics Inc. - Sorrento Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - ChironWells GmbH - Northern Light Pharmaceuticals AB For more information visit http://www.researchandmarkets.com/research/9s...ancer_pain
BDSI: 12.65 (+0.35), PFE: 30.67 (-0.19), AMGN: 159.44 (-0.16), AXN: 0.33 (+0.02), SRNE: 8.25 (+0.95), NKTR: 14.47 (-0.03), EGLT: 5.50 (-0.25), AZN: 69.56 (-0.18), VBAY: ()

Sorrento and Lee's Pharmaceutical Enter into Exclusive China Licensing Agreement to Develop and Commercialize Anti-PD-L1 antibody
PR Newswire - Fri Oct 03, 1:41PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that China Oncology Focus Limited, an Affiliate of Lee's Pharmaceutical Holdings Limited (Lee's Pharma), a public biopharmaceutical company listed on the main board of Hong Kong Stock Exchange (0950) with over 20 years of operation in China's pharmaceutical industry, has licensed Sorrento's fully human immune-oncology anti-PD-L1 monoclonal antibody (mAb) STI-A1014.
SRNE: 8.25 (+0.95)

Sorrento Therapeutics to Present at Two Healthcare Conferences
PR Newswire - Fri Sep 05, 7:45AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, announced today that Dr. Henry Ji, President and Chief Executive Officer of Sorrento, is scheduled to present a corporate overview at two upcoming conferences.
SRNE: 8.25 (+0.95)

Sorrento secures NIH grant to advance WISP1 in the Idiopathic Pulmonary Fibrosis programme
M2 - Wed Aug 27, 6:07AM CDT
Oncology company Sorrento Therapeutics (NASDAQ:SRNE) reported on Tuesday the receipt of a Small Business Innovation Research (SBIR) Phase 1 grant to advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) for the potential treatment of Idiopathic Pulmonary Fibrosis (IPF).
SRNE: 8.25 (+0.95)

Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF)
PR Newswire - Tue Aug 26, 7:45AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has received funding to advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) for the potential treatment of IPF, which affects more than 100,000 Americans. As this disease progresses, scarring in the lungs increases and patients gradually lose the ability to breathe, leading ultimately to death in two to five years after diagnosis.
SRNE: 8.25 (+0.95)

Data Published by Researchers from The Scripps Research Institute Demonstrate Potential for MYC Inhibitor Licensed by Sorrento Therapeutics
PR Newswire - Mon Aug 18, 6:45AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that data published in the Proceedings of the National Academy of Sciences (PNAS)1 demonstrate the potential for the MYC inhibitors that Sorrento licensed from The Scripps Research Institute (TSRI)2. The TSRI research team, led by Professors Kim D. Janda and Peter K. Vogt, reported in the study that function of the MYC regulator could be inhibited with small molecule compounds in cell culture and importantly in an experimental cancer animal model.
SRNE: 8.25 (+0.95)

Sorrento Therapeutics Appoints Douglas Ebersole to its Board of Directors
PR Newswire - Fri Aug 08, 4:00PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced the addition of industry veteran Douglas Ebersole to its Board of Directors.
SRNE: 8.25 (+0.95), PDLI: 7.32 (-0.07)

Sorrento condoles sudden death of its EVP Amar Singh
M2 - Fri Aug 01, 8:06AM CDT
Oncology company Sorrento Therapeutics (NASDAQ:SRNE) disclosed on Thursday the demise of Amar Singh, chief business officer and executive vice president, suddenly and unexpectedly on 30 July 2014.
SRNE: 8.25 (+0.95)

Sorrento Announces the Unexpected Death of its Chief Business Officer
PR Newswire - Thu Jul 31, 4:38PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) today announced the death of Mr. Amar Singh, Chief Business Officer and Executive Vice President. Mr. Singh died suddenly and unexpectedly of apparent natural causes on July 30.
SRNE: 8.25 (+0.95)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 137

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 21

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 184

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 319

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 168

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 114

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 196

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 142

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 191

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading

Top 5 Most Recently Viewed Articles

Crest Auto Group Teams Up with Football Star Kevin Jennings

Updated Category News Views 228

Crest Auto Group Partners with Rising Star Kevin Jennings Crest Auto Group, a renowned automotive dealership with a strong legacy in the industry, is taking a giant leap forward by announcing its inaugural collegiate Name, Image, and Likeness (NIL) partnership with the exceptional Kevin Jennings. As a team captain and quarterback, Jennings hails from a community that...

Continue Reading
Carolwood Estates Celebrates a Stellar 2024 Year of Growth

Updated Category News Views 390

Carolwood Estates Unveils Its 2024 Annual Report In a remarkable demonstration of resilience and success, Carolwood Estates has released its 2024 Annual Report, shining a spotlight on a fabulous year filled with record-breaking accomplishments. Under the leadership of CEO Drew Fenton, the brokerage has made notable strides within the competitive landscape of luxury real...

Continue Reading
Savage Appoints Josh Anders as Strategic Chief Financial Officer

Updated Category News Views 896

Welcoming Josh Anders to Savage Leadership Savage is thrilled to announce the appointment of Josh Anders as the new Chief Financial Officer (CFO) of the company. With a strong background in finance and a wealth of experience in various financial leadership roles, Anders is set to join the ranks of Savage’s effective global supply chain team. Experience and Leadership...

Continue Reading
John Hardin Enhances UBS Private Wealth Management Team in Miami

Updated Category News Views 91

UBS Welcomes New Financial Advisor in Miami UBS Private Wealth Management is making significant strides in enhancing its service offerings in South Florida with the inclusion of John Hardin as a Financial Advisor. This strategic move aims to bolster the firm's presence in Miami, strengthening relationships with clients and expanding the wealth management team. An...

Continue Reading
Investors Urged to Act by October: Hims & Hers Health Update

Updated Category News Views 270

Attention Hims & Hers Health Investors Investors holding shares in Hims & Hers Health, Inc. are urged to stay vigilant regarding significant developments affecting their investments. The Company, often simply referred to as Hims, is currently facing securities class action lawsuits filed by investors who believe they suffered financial losses during a specified period....

Continue Reading